GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

We recently published an article titled Jim Cramer Says AI Is Back & Discusses These 10 Stocks. In this article, we are going ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Shares have slumped 60% since the Wall Street Journal reported in April that the company was preparing to file for bankruptcy ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Shares of Eli Lilly and Company LLY slid 5.6% on the session’s health care slump. Shares of Newmont Corporation NEM, the world's largest gold miner, jumped 3%, adding to yesterday's gains, as the ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...

Cencora raised its 2025 earnings projection on strong U.S. demand for weight-loss drugs as quarterly net income jumped 71%. The drug wholesaler formerly known as AmerisourceBergen logged earnings of ...

LONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...